• Auranofin for Reliable Redox Assays

  2026-08-12

  Auranofin (SKU B7687) gives researchers a mechanistically defined way to investigate thioredoxin reductase inhibition, oxidative stress, apoptosis, and radiosensitization in cell-based assays. This scenario-driven guide explains how to select concentrations, manage solvent compatibility, interpret viability data, and assess product suitability without confusing biochemical potency with cellular response.

• GLT-1, CB1-CREB Signaling, and TBI Cognition

  2026-08-12

  A 2025 Biomolecules study identifies an astrocyte-centered mechanism linking post-traumatic 2-AG elevation to GLT-1 loss, glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction. Pharmacological blockade of CB1 with AM281 restored GLT-1 expression and improved behavioral outcomes, positioning the CB1-CREB-GLT-1 axis as a mechanistic target for memory impairment research.

• DiscoveryProbe Metabolism-related Compound Library Guide

  2026-08-11

  Discover how the DiscoveryProbe Metabolism-related Compound Library can convert redox, lipid, and PPAR signaling questions into better-controlled metabolic assays. Grounded in a cardiac ANP study, this guide presents a mechanism-first strategy for screening and validation.

• Adenosine Triphosphate: Designing Better Assays

  2026-08-10

  Adenosine Triphosphate (ATP) is more than a cellular energy carrier: it is a powerful experimental readout of metabolic state. This assay-centered guide connects ATP handling and interpretation with the 2025 TCAIM–OGDH discovery while defining practical boundaries for mitochondrial and signaling research.

• Chemistry of Silybin: Structure, Synthesis, and Uses

  2026-08-09

  Křen and colleagues’ review maps the chemistry of silybin from its isolation and stereochemical assignment to diastereomer resolution and extensive derivative synthesis. Its central practical lesson is that silybin and the broader milk thistle extract silymarin should not be treated as chemically interchangeable research materials, particularly in solubility, antioxidant, and biological assay design.

• Viral RIPK3 Degradation and Proteasome-Linked Inflammation

  2026-08-08

  Liu and colleagues identified a poxvirus-encoded viral inducer of RIPK3 degradation, or vIRD, that links the host SCF ubiquitin ligase machinery to the necroptosis kinase RIPK3. Their genetic and mouse infection experiments show that vIRD-dependent proteasomal turnover of RIPK3 can shape viral replication, inflammation, and mortality, providing a mechanistic framework for studying virus–host evolution.

• Uremic Metabolite Adsorption on Hydroxy-PEO Films

  2026-08-07

  The reference study examines how a multi-metabolite uremic environment changes adsorption to hydroxy-terminated polyethylene oxide films, rather than treating each toxin as an isolated analyte. Its results show that PEO chain density, exposure time, end-group chemistry, and metabolite structure jointly determine surface retention, with implications for designing blood-contacting materials under kidney-failure conditions.

• ONX-0914 (PR-957): Unlocking LMP7’s Impact in Translational

  2026-08-07

  Explore how selective LMP7 inhibition with ONX-0914 (PR-957) is transforming autoimmune and inflammatory research. This article weaves mechanistic insights, experimental evidence, and strategic guidance for translational scientists, leveraging new findings on airway epithelial immunoproteasomes to illuminate cross-domain opportunities and pitfalls.

• Lovastatin as an HMG-CoA Reductase Inhibitor in Research Wor

  2026-08-06

  Lovastatin empowers researchers to dissect cholesterol metabolism, apoptosis, and inflammatory cell behavior with nanomolar potency and broad mechanistic reach. This guide delivers actionable workflows, advanced troubleshooting, and integration with emerging hormonal regulation studies, distinguishing APExBIO’s Lovastatin as a trusted standard.

• AG-120 (Ivosidenib): Optimizing IDH1-Mutant AML Assays

  2026-08-06

  AG-120 (Ivosidenib) empowers researchers to precisely inhibit mutant IDH1 and robustly reduce 2-hydroxyglutarate in AML models. This guide translates breakthrough metabolic rewiring insights into actionable protocols, advanced troubleshooting, and comparative perspectives to accelerate discovery and data reliability.

• Direct Mouse Genotyping Kit Plus: Precision for Complex Mode

  2026-08-05

  Explore how the Direct Mouse Genotyping Kit Plus enables rapid, purification-free mouse genotyping and empowers advanced genetic studies. This article reveals unique assay considerations and translational insights for cardiovascular and immunology research.

• CD28-ARS2 Axis Controls PKM Splicing for T Cell Antitumor Im

  2026-08-05

  This study elucidates how the CD28-ARS2 signaling axis governs alternative splicing of pyruvate kinase in CD8+ T cells, favoring the PKM2 isoform to enhance metabolic flexibility and antitumor activity. The findings establish a PI3K-independent pathway for metabolic reprogramming in effector T cells, with significant implications for immunometabolic research and therapeutic modulation.

• CDK9 inhibitor (A3294): Selective Transcription Elongation T

  2026-08-04

  CDK9 inhibitor (A3294) provides selective, non-cytotoxic inhibition of cyclin dependent kinase 9, enabling precise studies of transcription elongation and HIV-1 propagation in cell-based workflows. It is not suitable for broad-spectrum CDK inhibition or protocols requiring long-term storage of working solutions. Researchers benefit from its high target selectivity and well-documented solubility profile.

• ATP Solution Empowers Kinase & mRNA Workflows in Oncology

  2026-08-04

  APExBIO’s ATP Solution (100 mM) delivers unrivaled purity and stability for critical kinase, in vitro transcription, and phosphorylation assays. This guide unpacks actionable workflows and troubleshooting insights, spotlighting its role in advanced mRNA-LNP bladder cancer research.

• AG-120 (Ivosidenib): Redefining IDH1 Mutant AML Targeting

  2026-08-03

  This thought-leadership article explores the mechanistic underpinnings and translational strategies for targeting mutant IDH1-driven acute myeloid leukemia (AML) using AG-120 (Ivosidenib). Integrating new evidence on CD44-mediated metabolic rewiring, the discussion provides actionable guidance for translational researchers, highlighting AG-120’s relevance, workflow parameters, and the evolving landscape of resistance mechanisms in IDH1-mutant cancers.

448 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page